J
Janet Dancey
Researcher at Queen's University
Publications - 192
Citations - 40082
Janet Dancey is an academic researcher from Queen's University. The author has contributed to research in topics: Cancer & Temsirolimus. The author has an hindex of 68, co-authored 185 publications receiving 33841 citations. Previous affiliations of Janet Dancey include National Institutes of Health & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Frances A. Shepherd,Janet Dancey,Rodryg Ramlau,Karin Mattson,Richard J. Gralla,Mark Allen O'Rourke,Nathan Levitan,Laurent Gressot,Mark Vincent,Ronald L. Burkes,Susan Coughlin,Yong Kim,Jocelyne Berille +12 more
TL;DR: Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m(2), the benefits of docetAXel therapy outweigh the risks.
Journal ArticleDOI
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour,Jan Bogaerts,Andrea Marie Perrone,Robert Ford,Lawrence H. Schwartz,Lawrence H. Schwartz,Sumithra J. Mandrekar,Nan Lin,Saskia Litière,Janet Dancey,Alice P. Chen,F. Stephen Hodi,Patrick Therasse,Otto S. Hoekstra,Lalitha K. Shankar,Jedd D. Wolchok,Marcus Ballinger,Marcus Ballinger,Marcus Ballinger,Caroline Caramella,Elisabeth G.E. de Vries +20 more
TL;DR: This guideline describes a standard approach to solid tumour measurements and definitions for objective change in tumour size for use in trials in which an immunotherapy is used and defines the minimum datapoints required from future trials to facilitate the compilation of a data warehouse to later validate iRECIST.
Journal ArticleDOI
RECIST 1.1—Update and clarification: From the RECIST committee
Lawrence H. Schwartz,Lawrence H. Schwartz,Saskia Litière,Elisabeth G.E. de Vries,Robert Ford,Stephen J. Gwyther,Sumithra J. Mandrekar,Lalitha K. Shankar,Jan Bogaerts,Alice P. Chen,Janet Dancey,Wendy Hayes,F. Stephen Hodi,Otto S. Hoekstra,Erich P. Huang,Nan Lin,Yan Liu,Patrick Therasse,Jedd D. Wolchok,Lesley Seymour +19 more
TL;DR: The purpose of this paper was to summarise the questions posed and the clarifications provided as an update to the 2009 publication of Response Evaluation Criteria in Solid Tumours.
Journal ArticleDOI
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Jeremy N. Rich,David A. Reardon,Terry S. Peery,Jeannette M. Dowell,Jennifer A. Quinn,Kara Penne,Carol J. Wikstrand,Lauren B. Van Duyn,Janet Dancey,Roger E. McLendon,James C. Kao,Timothy T. Stenzel,B.K. Ahmed Rasheed,Sandra Tourt-Uhlig,James E. Herndon,James J. Vredenburgh,John H. Sampson,Allan H. Friedman,Darell D. Bigner,Henry S. Friedman +19 more
TL;DR: Gefitinib is well tolerated and has activity in patients with recurrent glioblastoma and further study of this agent at higher doses is warranted.